Edward Hines Jr. VA Hospital, Hines, IL 60141, USA.
Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Curr Oncol. 2024 Aug 21;31(8):4781-4794. doi: 10.3390/curroncol31080358.
The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed a phase II/III RCT to test the use of metastasis-directed therapy in Veterans with oligometastatic prostate cancer (OMPC)-the first VA RCT in OMPC that leverages novel imaging and advanced radiotherapy techniques. To accomplish this, we developed a clinical trial network to conduct the study. In this manuscript, we describe several challenges we encountered in study development/conduct and our strategies to address them, with the goal of helping investigators establish robust study networks to conduct clinical trials. In the study start-up, we encountered challenges in timely site activation, and leveraged project management to maximize efficiency. Additionally, there were several changes in the clinical paradigms in imaging and treatment that led to protocol amendments to ensure maximum equipoise, recruitment, and impact of the study. Specifically, we amended the trial to add de novo OMPC patients (from initially only recurrent OMPC) and expanded the study to allow up to 10 metastases (from initially five). Finally, in order to maintain local study team engagement, we developed initiatives to maximize collaboration and add value to the overall clinical program through study participation.
美国退伍军人事务部(VA)医疗保健系统在开展有影响力的肿瘤学随机临床试验(RCT)方面有着悠久的历史。我们开展了一项 II/III 期 RCT,以测试转移性前列腺癌(OMPC)退伍军人使用转移性定向治疗的效果 - 这是 VA 在 OMPC 中开展的首个利用新型影像学和先进放疗技术的 RCT。为了实现这一目标,我们开发了一个临床试验网络来进行这项研究。在本文中,我们描述了在研究开发/实施过程中遇到的一些挑战以及我们解决这些挑战的策略,旨在帮助研究人员建立强大的研究网络来开展临床试验。在研究启动阶段,我们在及时激活站点方面遇到了挑战,并利用项目管理来提高效率。此外,影像学和治疗方面的临床范例发生了一些变化,导致方案修订以确保最大的均衡性、招募和研究的影响。具体来说,我们修改了试验以纳入新诊断的寡转移前列腺癌患者(最初只纳入复发性寡转移前列腺癌患者),并扩大了研究范围,允许最多有 10 个转移灶(最初为 5 个)。最后,为了保持当地研究团队的参与度,我们制定了各种举措,通过参与研究来最大限度地促进合作并为整个临床项目增加价值。